| Name | Title | Contact Details |
|---|---|---|
Shawn Kernes |
Chief Technology Officer | Profile |
Kickstarter aims to let creative people of all kinds — journalists, artists, musicians, game developers, entrepreneurs, bloggers — raise money for their projects by connecting directly with fans, who receive exclusive access and rewards in exchange for their patronage. More than just a fundraising app, Kickstarter`s a publishing platform where project creators can communicate with the people that are supporting them.
Crosswicks Creek Design is a Crosswicks, NJ-based company in the Software and Internet sector.
Novariant, Inc. emerged from Stanford University GPS Laboratory in 1994 to pursue contract research and development for precision vehicle control systems. In the early 1990s, the Federal Aviation Administration (FAA) asked Stanford to investigate the feasibility of automatically landing airliners in low visibility conditions using precision GPS.
Combining a powerful cross-channel marketing campaign management solution with market-leading data access and analysis, StrongView (formerly StrongMail) enables enterprise marketers to understand the current context of each customer and respond in real time with relevant messages across email, mobile, social, display and web. Headquartered in Redwood City, CA with offices in New York and the United Kingdom, StrongView has been helping global brands in retail, travel, finance, entertainment and online services overcome the limitations of other marketing platform providers for more than a decade.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.